A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS Autoantibodies against the zinc transporter 8 (ZnT8A) are common in type 1 diabetes (T1D). ZnT8A analyses are complicated by the fact that there are three variants of the autoantigen at amino acid position 325 representing ZnT8-R (Arginine), ZnT8-W (Tryptophan) and ZnT8-Q (Glutamin). The aims of the study were: 1) to develop an autoantigen triple mix Radio-Binding Assay (RBA) for ZnT8A; 2) to identify the individual ZnT8-R,-W,-QA reactivity and 3) to validate the triple mix ZnT8A RBA in children with newly diagnosed T1D. METHODS Serum samples were obtained from 2664 (56% males, n=1436) patients in the Swedish nationwide Better Diabetes Diagnosis (BDD) study representing patients with T1D (97%, n=2582), T2D (1.7%, n=46), MODY (1.0%, n=28) and secondary diabetes (0.3%, n=8). cDNA coding for the C-terminal end of each variant was prepared by site-directed mutagenesis and subcloned into a high efficiency in vitro transcription translation vector. The ZnT8 variants were labeled with 35S-methionine and used in a standard RBA separating free from autoantibody-bound autoantigen with Protein A-Sepharose. RESULTS ZnT8-TripleA was detected in 1678 (65%) patients with T1D, 4 (9%) T2D, 3 (11%) MODY and in none (0%) of the patients with secondary diabetes. Among the T1D patients ZnT8-RA was detected in 1351 (52%) patients, ZnT8-WA in 1209 (47%) and ZnT8-QA in 790 (31%) demonstrating that 1661 (64%) had one or several ZnT8A. The ZnT8-TripleA assay showed a false positive rate of 1.9% (n=49). Only 1.2% (n=32) of the T1D patients were false negative for ZnT8-TripleA compared to 0/46 (0%) of the T2D patients. The precision (intra assay CV) and reproducibility (inter assay CV) of the ZnT8-TripleA assay did not differ from the RBA of the individual ZnT8 variants. CONCLUSION We conclude that the ZnT8-TripleA assay had low false positive and false negative rates. The ZnT8-TripleA assay would therefore be highly suitable not only to analyze patient with newly diagnosed diabetes but also for screening the general population since this assay demonstrated high sensitivity and very high specificity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rewers, M., Bugawan, T. L., Norris, J. M., Blair, A., Beaty, B., Hoffman, M., McDuffie, R. S., Hamman, R. F., Klingensmith, G., Eisenbarth, G. S., et al. (1996) · Diabetologia · doi:10.1007/s001250050514 · Cited by 422 · cited 3×
“This assaymay also prove useful for the detection of ZnT8A in observational clinical trials such as TEDDY (2008), BABYDIAB (Schenker et al., 1999), DAISY (Rewers et al., 1996) and DiPiS (Larsson et al., 2004), ABIS (Ludvigsson et al., 2001) as well as in prevention and intervention clinical trials when islets autoanti…”
BackgroundGrubin, C. E., Daniels, T., Toivola, B., Landin-Olsson, M., Hagopian, W. A., Li, L., Karlsen, A. E., Boel, E., Michelsen, B., & Lernmark, �. (1994) · Diabetologia · doi:10.1007/bf00408469 · Cited by 415
Self-citationWenzlau, J. M., Liu, Y., Yu, L., Moua, O., Fowler, K. T., Rangasamy, S., Walters, J., Eisenbarth, G. S., Davidson, H. W., & Hutton, J. C. (2008) · Diabetes · doi:10.2337/db08-0522 · Cited by 205 · cited 3×
“ZnT8A were detected in 63% of newly diagnosed T1D patients, but also in 3% of T2D patients and 3% of healthy controls (Wenzlau et al., 2008b).”
BackgroundGrijse, D. (2010) · doi:10.1007/s00125-009-1618-y · Cited by 94
Cited by
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Self-citationHuang, L., & Tepaamorndech, S. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.05.008 · Cited by 343
Shepherd, M., Shields, B., Hammersley, S., Hudson, M., McDonald, T. J., Colclough, K., Oram, R. A., Knight, B., Hyde, C., Cox, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0645 · Cited by 236
“3% had type 2 diabetes, a figure that is very similar to the number of individuals with monogenic diabetes, as seen in other European populations (7,24,33).”
BackgroundCarlsson, A., Shepherd, M., Ellard, S., Weedon, M., Lernmark, Å., Forsander, G., Colclough, K., Brahimi, Q., Valtonen-Andre, C., Ivarsson, S. A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0747 · Cited by 111
Self-citationAndersson, C., Kolmodin, M., Ivarsson, S.-A., Carlsson, A., Forsander, G., Lindblad, B., Ludvigsson, J., Kockum, I., Marcus, C., Samuelsson, U., et al. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12093 · Cited by 44
Self-citation
Metadata
- Authors
- Vaziri-Sani, F., Delli, A. J., Elding-Larsson, H., Lindblad, B., Carlsson, A., Forsander, G., Ivarsson, S. A., Ludvigsson, J., Marcus, C., & Lernmark, Å.
- Venue
- Journal of Immunological Methods
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 371
- Issue
- 1-2
- Pages
- 25-37
- ISSN
- 0022-1759 (ISSN-L)
- OpenAlex
- W2155496433
- Cited by
- 69
- References
- 4
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. https://app.cochat.ai/papers/10.1016/j.jim.2011.06.011
- The paper
- Vaziri-Sani, F., Delli, A. J., Elding-Larsson, H., Lindblad, B., Carlsson, A., Forsander, G., Ivarsson, S. A., Ludvigsson, J., Marcus, C., & Lernmark, Å. (2011). A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. Journal of Immunological Methods. https://doi.org/10.1016/j.jim.2011.06.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.